Amneal Launches Generic for Tamiflu® Oral Suspension

March 01, 2018

Bridgewater, NJ (USA), March 1, 2018 – Amneal Pharmaceuticals has launched oseltamivir phosphate for oral suspension, the company’s AB-rated therapeutic equivalent for Tamiflu®, in a 6 mg/mL strength. The powder finished dosage form is made in the U.S.A. and packaged in bottles providing 60 mL of usable volume after constitution. Amneal’s oseltamivir phosphate for oral suspension joins its oral solid capsule form approved and launched in July 2017.

“Approval and launch of this liquid form should be of great assistance to patients and caregivers,” states Amneal EVP of Commercial Operations Andy Boyer. “With a severe flu season upon us, our product should be able to help provide relief to thousands of patients. We are pleased to provide this liquid dosage form to patients, particularly the elderly and young who are unable to use an oral solid form.”

Annual U.S. sales of Tamiflu® and its generic equivalents were $956 million, according to December 2017 IQVIA™ market data.